Diamantis is a Founding Partner & Head of Research at Catalio Capital Management, LP. He is responsible for managing Catalio’s Investment Team and investing in breakthrough biomedical technology companies. He serves on the Investment Committee of Catalio’s flagship Nexus strategy and on the firmwide Management Committee. Diamantis previously served on the Board of Haystack Oncology and currently serves on the Boards of Spiral Therapeutics, Sickbay, TBD Pharma, Cage Tx, and Avalyn Pharma. He was previously a surgical resident at Johns Hopkins Hospital, after earning his Medical Degree at Imperial College School of Medicine in London, and a degree in Healthcare Management from Imperial College Business School.